Agentix Corp. warns of going-concern as cash falls to $4,412 despite rising R&D

Agentix Corp. (PINK: AGTX) - Quick take

Agentix Corp. is a clinical-stage biotech with no reported revenue for the quarter ended June 30, 2025. The quarter shows rising R&D activity but weak liquidity, significant related‑party funding and a formal going‑concern disclosure.

Key facts & figures
* Shares outstanding: 40,066,951
* Cash (6/30/2025): $4,412 (beginning of period $4,477)
* Total current assets (6/30/2025): $4,412; Total assets: $4,412
* Total current liabilities (6/30/2025): $3,276,178; Total liabilities: $3,276,178
* Accounts payable: $700,149; Accounts payable - related parties: $2,148,663
* Note payable - related party (principal): $343,000 (interest accrued $83,359 included in accrued expenses)
* Accumulated deficit (6/30/2025): $(6,707,352)
* Total stockholders' deficit: $(3,271,766)
* Operating expenses (Q): $200,342 vs $151,305 (prior year)
* R&D expense (Q): $100,000 vs $55,501 (prior year)
* Professional fees (Q): $82,625 vs $77,000 (prior year)
* Loss from operations (Q): $(200,342) vs $(151,305)
* Net loss (Q): $(185,824) vs $(150,717)
* Net cash provided by (used in) operating activities: $(118,371) vs $(2,400) prior year
* Net cash from financing activities: $100,000 (proceeds from debt)

Positive signals
* Management increased R&D spend to $100,000 (up from $55,501) - indicates active development work.
* Other income of $20,604 recognized (gain on settlement of accounts payable) partially offset expenses.
* Accumulated other comprehensive income improved to $53,688 (foreign currency translation gain of $18,307), which reduced total comprehensive loss.
* Company secured $100,000 in debt financing during the quarter (short‑term liquidity relief).

Negative / Risk items (material)
* No revenues reported for the quarter - company remains pre‑revenue.
* Very low cash balance: $4,412 - insufficient to cover near‑term obligations.
* Large related‑party payables and advances: $2,148,663 in accounts payable-related parties (SBS Management, Gray's Peak, management). These are unsecured and with no formal repayment terms.
* Short-term related‑party note outstanding $343,000 with high interest accruals; notes are secured by substantially all company assets and senior to other creditors.
* Net loss $(185,824) and negative operating cash flow $(118,371) - operating burn increased vs prior year.
* Stockholders' deficit $(3,271,766) and accumulated deficit $(6,707,352) - equity position is negative.
* Management concluded disclosure controls and procedures were not effective as of June 30, 2025.
* Going concern: the company explicitly states substantial doubt about its ability to continue without additional financing; cash position and negative working capital highlight immediate financing need.

Related‑party funding detail
* SBS Management LLC advances/fees to Company: $96,103 expense in Q and $1,261,594 included in related‑party payables at 6/30/2025.
* Gray's Peak Capital advances included $516,262 in related‑party payables at 6/30/2025; Gray's Peak mezzanine note principal outstanding $343,000 (accrued interest $83,359 included in accrued expenses).
* Notes with Gray's Peak are secured by substantially all assets, senior to unsecured creditors and equity.

What's happening inside the company - straight answer
Agentix is spending more on R&D and professional services while remaining pre‑revenue. Operations are funded largely via related‑party advances and short‑term debt. Management is actively trying to advance development but has run out of meaningful cash on hand and faces a near‑term funding cliff. The balance sheet shows negative equity and material related‑party exposure; internal controls were judged ineffective. Management acknowledges they must raise capital (equity or debt) to continue; failure to secure financing would likely end operations.

Immediate watch items for investors
* Cash runway: $4,412 on hand - immediate liquidity shortfall.
* Related‑party obligations and Gray's Peak note maturity/terms (note extended to Dec 31, 2025) - potential for enforcement of security or acceleration.
* Any announced equity raises (dilution) or new debt (terms, collateral).
* Progress milestones in R&D that could attract partners or non‑dilutive funding.
* Remediation of disclosure controls (currently not effective).

Bottom line: Agentix Corp. remains a pre‑revenue biotech in active development. The quarter shows increased investment in R&D but an acute liquidity crisis, heavy reliance on related‑party funding, rising interest expense and a formal going‑concern warning. The company needs fresh capital immediately to avoid failure or severe dilution.